Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 11, 2016, Pages

  Weston, Jennifer ^a   Bromley, Rebecca ^b   Jackson, Cerian F ^a   Adab, Naghme ^c   Clayton Smith, Jill ^b   Greenhalgh, Janette ^a   Hounsome, Juliet ^a   Mckay, Andrew J ^d   Tudur Smith, Catrin ^a   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c WALSGRAVE HOSPITAL   (United Kingdom)

^d ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LEVETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

COCHRANE LIBRARY; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; DOSE RESPONSE; EMBASE; EPILEPSY; HIGH RISK PATIENT; HUMAN; LIMB MALFORMATION; MEDLINE; META ANALYSIS; MONOTHERAPY; NEURAL TUBE DEFECT; OBSERVATIONAL STUDY; OROFACIAL MALFORMATION; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SKELETON MALFORMATION; SYSTEMATIC REVIEW; CARDIOVASCULAR MALFORMATION; CLASSIFICATION; DRUG INDUCED MALFORMATION; FEMALE; MUSCULOSKELETAL SYSTEM MALFORMATION; NEWBORN; PREGNANCY COMPLICATIONS;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CARDIOVASCULAR ABNORMALITIES; CRANIOFACIAL ABNORMALITIES; EPILEPSY; FEMALE; HUMANS; INFANT, NEWBORN; MUSCULOSKELETAL ABNORMALITIES; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84994509573     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010224.pub2     Document Type: Review

References (173)

1. Al Bunyan M, Abo-Talib Z. Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure 1999;8:26-29. [4393577]
2. Arulmozhi T, Dhanaraj M, Rangaraj R, Vengatesan A. Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India 2006;54(1):42-46. [4393579]
3. Vajda F, Lander C, O'Brien T, et al. Australian Pregnancy Registry of Women Taking Antiepileptic Drugs. Epilepsia 2004;45(11):1466. [4393581]
4. Vajda F, O'Brien T, Graham J, Lander C, Eadie M. Dose dependence of fetal malformations associated with valproate. Neurology 2013;81:999-1003. [4393582]
5. Vajda F, O'Brien T, Lander C, Graham J, Roten A, Eadie M. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013c;54(1):181-186. [4393583]
6. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. Journal of Clinical Neuroscience 2003;10(5):543-549. [4393584]
7. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. Journal of Clinical Neuroscience 2004;11(8):854-858. [4393585]
8. Vajda FJE, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005;112:137-143. [4393586]
9. Vajda FJE, Graham J, Lander CM, O'Brien TJ, Eadie M. Teratogenicity of the newer antiepileptic drugs- the Australian experience. Journal of Clinical Neuroscience 2012;19:57-59. [4393587]
10. Vajda FJE, Graham JE, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure 2010;19:558-561. [4393588]
11. Vajda FJE, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnanacy: The first 1002 pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology 2007;47:468-474. [4393589]
12. Vajda FJE, Lander CM, Hitchcock A, et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. Journal of Clinical Neuroscience 2007;14:611-617. [4393590]
13. Vajda FJE, O'Brien TJ, Graham J, Lander CM, Eadie MJ. Prediction of the hazard of foetal malformation in pregnant women with epilepsy. Epilepsy Research 2014;108(6):1013-1017. [4393591]
14. Vajda FJE, O'Brien TJ, Lander CM, Eadie MJ. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand 2013b;128:228-234. [4393592]
15. Bag S, Behari M, Ahuja GK, Karmarkar MG. Pregnancy and epilepsy. Journal of Neurology 1989;236:311-313. [4393594]
16. Barqawi R. Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. Eastern Mediterranean Health Journal 2005;11(4):601-605. [4393596]
17. Bozhinov P, Bozhinova S, Markova C. Fetal malformations in women with epilepsy. Akusherstvo i Ginekologiia 2009;48(1):16-21. [4393598]
18. Battino D, Binelli S, Caccamo ML, et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand 1992;85:204-207. [4393600]
19. Battino D, Kaneco S, Andermann E, et al. Intrauterine growth in the offspring of epileptic women: a prospective multicentre study. Epilepsy Research 1999;36:53-60. [4393601]
20. Canger R, Battino D, Canevini MP, et al. Malformations in Offspring of Women with Epilepsy: A Prospective Study. Epilepsia 1999;40(9):1231-1236. [4393602]
21. Cassina M, Dilaghi A, Gianantonio E, et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reproductive Toxicology 2013;39:50-57. [4393604]
22. D'Souza SW, Robertson IG, Donnai D, Mawer G. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood 1990;65:320-324. [4393606]
23. Đelmiš J, Dražančić A, Tkalčević T, Ivanišević M. Epilepsy in Pregnancy [Epilepsija I Trudnoća]. Jugosl ginekol perinatal 1991;31(1-2):23-26. [4393608]
24. Diaz-Romero RM, Garza-Morales S, Mayen-Molina DG, Ibarra-Puig J, Avila-Rosas H. Facial Anthropometric Measurements in Offspring of Epileptic Mothers. Archives of Medical Research 1999;30:186-189. [4393610]
25. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: A French prospective cohort study. Neurology 1992;42 (suppl 5):75-82. [4393612]
26. Eroglu E, Gokcil Z, Bek S, Hidir Ulas U, Odabasi Z. Pregnancy and teratogenicity of antiepileptic drugs. Acta Neurol. Belg. 2008;108:53-57. [4393614]
27. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, for the EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10:609-17. [4393616]
28. Tomson T, Battino D, Bonizzoni E, Craig JJ, Lindhout D, Perucca E, et al. Antiepileptic drugs and intrauterine death. Neurology 2015;85(7):580-8. [4393617]
29. Fairgrieve SD, Jackson M, Jonas P, Walshaw D, White K, Montgomery M, Burn J, Lynch SA. Population based, prospective study of the care of women with epilepsy in pregnancy. British Medical Journal 2000;321:674-675. [4393619]
30. Froescher W, Herrmann R, Neisen M, Buelau P, Penin H, Hildenbrand G. The course of pregnancy and teratogenicity of antiepileptic agents in 66 patients with epilepsy [Untersuchungen zum schwangerschaftsverlauf und zer teratogenitat der antiepileptika bei 66 epilepsie-patientinnen]. Schweizer Archiv fur neurologie und psychiatrie 1991;142(5):389-407. [4393621]
31. Fujji H, Goel A, Bernard N, Pistelli A, Yates L, Stephens S, Han J, Matsui D, Etwell F, Einarson T, Koren G, Einarson A. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013;80(1):565-1570. [4393623]
32. Gaily E. Distal Phalangeal Hypoplasia in Children With Prenatal Phenytoin Exposure: Results of a Controlled Anthropometric Study. American Journal of Medical Genetics 1990;35:574-578. [4393627]
33. Gaily E, Granstrom M-L, Hiilesmaa V, Bardy A. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Research 1990;5:217-222. [4393625]
34. Gaily E, Granstrom M-L, Hiilesmaa V, Bardy A. Minor anomalies in offspring of epileptic mothers. Journal of Pediatrics 1988;112(4):520-529. [4393626]
35. Hilemsmaa V, Bardy AH, Teramo K. Obstetric outcome in women with epilepsy. American Journal of Obstetrics and Gynecology 1985;152(5):499-504. [4393628]
36. Hilemsmaa V, Teramo K, Granstrom ML, Bardy AH. Serun folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures and fetal outcome. British Medical Journal 1988;287:577-578. [4393629]
37. Garza-Morales S, Ibarra-Puig JM, Poblano-Luna A, Mayen-Molina G, Cordova-Lopez S. Epilepsy and pregnancy: prospective study of 100 cases [Epilepsia y embarazo. Estudio prospectivo 100 casos]. Ginecologia U Obstetricia de Mexico 1996;64:449-454. [4393631]
38. Goujard J, Huel G, Rumeau-Rouquette C. Antiepileptics and congenital malformations [Antiepileptiques et malformations congenitales]. Journal of Gynecology Obstetrics and Biological Reproduction 1974;3:831-842. [4393633]
39. Hill RM, Verniaud WM, Horning MG, McCulley LB, Morgan NF. Infants Exposed in Utero to Antiepileptic Drugs. American Journal of Diseases of Children 1974;127:645-653. [4393635]
40. Diav-Citrin O, Shechtman S, Arnon J, et al. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001;57:321-324. [4393637]
41. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy Outcome after in utero Exposure to Valproate. CNS Drugs 2008;22(4):325-334. [4393638]
42. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood 1996;75:517-520. [4393639]
43. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O. The outcome of pregnancy following topiramate treatment: A study on 52 pregnancies. Reproductive Toxicology 2008;25:388-389. [4393640]
44. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine 1989;320(25):1661-1666. [4393642]
45. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003;60:575-579. [4393644]
46. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Research 1999;33:141-158. [4393646]
47. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29(4):459-467. [4393647]
48. Kaneko S, Otani K, Hirano T, Kondo T, Fukushima Y, Nakamura Y, Ogawa Y, Saito Y, Kan R, Kumashiro H, Takeda A, Nakane Y, Tsuiki H, Tsurusaki M, Teranishi T, Goto M. Teratogenicity of antiepileptic drugs: is prevention possible. The Japanese Journal of Psychiatry and Neurology 1991;45(2):478-481. [4393648]
49. Kaneko S, Otani K, Kondo T, Fukushima Y, Kan R, Takeada A, Nakane Y. Teratogenicity of antiepileptic drugs and drug specific malformations. The Japanese Journal of Psychiatry and Neurology 1993;47(2):306-309. [4393649]
50. Kaneko S, Otani K, Kondo T, Fukushima Y, Ogawa Y, Kan R, Takeada A, Nakene Y, Teranishi T. Malformations in infants of mothers with epilepsy. Neurology 1992;42(supp 5):68-74. [4393650]
51. Kelly T, Edwards P, Rein M, Miller JQ, Dreifuss FE. Teratogenicity of Anticonvulsant Drugs. II: A Prospective Study. American Journal of Medical Genetics 1984;19:435-443. [4393652]
52. Begum S, Sarma S, Thomas S. Malformation in index pregnancy in women with epilepsy is not followed by recurrence in subsequent pregnancy. Epilepsia 2013;54(12):163-167. [4393654]
53. Thomas SV, Ajaykumar B, Sindhu K, et al. Cardiac Malformations Are Increased in Infants of Mothers with Epilepsy. Pediatr Cardiol 2008;29:604-608. [4393655]
54. Thomas SV, Indrani L, Devi GC, et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurology India 2001;49(1):60-66. [4393656]
55. Jager-Roman E, Deichi A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. Pediatric Pharmacology and Therapeutics 1986;108:997-1004. [4393658]
56. Koch S, Gopfert-Geyer I, Jager-Roman E, et al. [Antiepileptika wahrend der Schwangerschaft]. Dtsch. Med. Wochenschr 1983;108(7):250-257. [4393659]
57. Koch S, Losche G, Jager-Roman E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992;42(5):83-88. [4393660]
58. Kuhnz W, Jager-Roman E, Rating D, et al. Carbamazepine and Carbamazepine-10, 11-Epoxide During Pregnancy and Postnatal Period in Epileptic Mothers and Their Nursed Infants: Pharmacokinetics and Clinical Effects. Pediatric Pharmacology 1983;3:199-208. [4393661]
59. Kuhnz W, Koch S, Jakob S, Hartmann A, Helge H, Nau H. Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology 1984;18:671-677. [4393662]
60. Rating D, Jager-Roman E, Koch S, et al. Major malformations and minor anomalies in the offspring of epileptic parents: The role of antiepileptic drugs. Pharmacokinetics in Teratogenesis 1987;1:205-223. [4393663]
61. Rating D, Nau H, Jager-Roman E, Gopfert-Geyer I, Koch S, Beck-Mannagetta G, Schmidt D, Helge H. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavia 1982;71:301-311. [4393664]
62. Laskowska M, Leszczynska-Gorzelak B, Oleszczuk J. Evaluation of the antiepileptic therapy during pregnancy [Ocena terapii przeciwpadaczkowej w okresie ciazy]. Gin Pol. 2002;73(1):35-42. [4393666]
63. Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of Antiepileptci Drug Combinations with Special Emphasis on Epoxidation (of Carbamazepine). Epilepsia 1984;25(1):77-83. [4393668]
64. Lindhout D, Meinardi H, Meijer JWA, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992;42(5):94-110. [4393669]
65. Martinez Ferri M, Pena Mayor P, Perez Loppez-Fraile, Castro Vilanova C, Escartin Siquier E, Martin Moro M, Forcadas Berdusan F. [Malformaciones y muerte fetal en el registro espanol de farmacos antiepilepticos y embarazo: resultados a los 6 anos]. Neurologia 2009;24(6):360-365. [4393671]
66. Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: Obstetric and neonatal outcome of a controlled study. Seizure 2010;19:112-119. [4393673]
67. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: Fetal death and malformations. Neurology 2006;67:407-412. [4393675]
68. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy & Behaviour 2004;5:163-167. [4393677]
69. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, Folate Levels, and Pregnancy Outcome: A Prospective Study. Annals of Neurology 1987;21:176-182. [4393679]
70. Oguni M, Dansky L, Andermann E, Sherwin A, Andermann F. Improved Pregnancy Outcome in Epileptic Women in the Last Decade: Relationship to Maternal Anticonvulsant Therapy. Brain & Development 1992;14:371-380. [4393680]
71. Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: A prospective study. Reproductive Toxicology 1992;6:257-261. [4393682]
72. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in Children Exposed In Utero to Phenytoin and Carbamazepine Monotherapy: Independent Effects of Epilepsy and Medications. American Journal of Medical Genetics 1997;68:18-24. [4393683]
73. Bokhari A, Coull BA, Holmes LB. Effect of Prenatal Exposure to Anticonvulant Drugs on Dermal Ridge Patterns of Fingers. Teratology 2002;66:19-23. [4393685]
74. Bromfield EB, Dworetzky BA, Wyszynski DF, Smith CR, Baldwin EJ, Holmes LB. Valproate teratogenicity and epilepsy syndrome. Epilepsia 2008;49(12):2122-2124. [4393686]
75. Hernandez-Diaz S, Mittendorf R, Smith C, Hauser W, Yerby M, Holmes L. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstetrics & Gynecology 2014;123(1):21-28. [4393687]
76. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-1699. [4393688]
77. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152-2158. [4393689]
78. Holmes LB, Coull BA, Dorfman J, Rosenberger PB. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. The Journal of Paediatrics 2005;146:118-122. [4393690]
79. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal Effects of Anticonvulsant Polytherapies. Archives of Neurology 2011;68(10):1275-1281. [4393691]
80. Holmes LB, Rosenberger PB, Harvey EA, Khoshbin S, Ryan L. Intelligence and Physical Features of Children of Women With Epilepsy. Teratology 2000;61:196-202. [4393692]
81. Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry. Epilepsia 2004;45(11):1465. [4393693]
82. Wyszynski DF, Nambisan M, Surve T, et al. Increase rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965. [4393694]
83. Omtzigt JGC, Los FJ, Grobbee DE, Pijpers L, Jahoda MGJ, Brandonburg H, Stewart P, Gaillard HLJ, Sachs ES, Wladimiroff JW, Lindhout D. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(supp 5):119-125. [4393696]
84. Omtzigt JGC, Los FJ, Hagenaars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenatal diagnosis 1992;12:893-897. [4393697]
85. Pardi G, Como ML, Giambattista MDE, Oldrini A, Pifarotti G. Epilepsy in pregnancy: obstetric aspects of a multidisciplinary study [Epilessia e gravidanza: aspetti ostrtrici di uno studio prospettico multidisciplinare]. Ann Ost Gin Med Perin 1982;CIII:254-263. [4393699]
86. Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A. Epilepsy and pregnancy: An obstetric perspective. American Journal of Obstetrics and Gynecology 2004;190:371-379. [4393701]
87. Sabers A, Dam M, a-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurologica Scandinavica 2004;109:9-13. [4393703]
88. Samren EB, van Duijn CN, Koch S, Hiilesmaa VK, Klepel H, Vardy AH, Beck Mannagettta G, Deichl AW, Gaily E, Granstrom ML, Meinardi H, Grobbe DE, Hofman A, Janz D, Lindhout D. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38(9):981-990. [4393705]
89. Shapiro S, Hartz S, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. The Lancet 1976;1(7954):272-275. [4393707]
90. Steergers-Theunissen RPM, Renier WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: A multi-centre prospective study. Epilepsy Research 1994;18:261-269. [4393709]
91. Regesta G, Tanganelli P. The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Boll Lega It Epil 1996;95/96:351-354. [4393711]
92. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: An Italian prospective, controlled study. Neurology 1992;42(5):89-93. [4393712]
93. Torres LC, Felix R, Canun S, Mazon JJ. Epilepsy and pregnancy. Risks and benefits of anticonvulsant treatments [Epilepsia y embarazo. Riegos y beneficios del tratamiento anticonvulsivo]. Ginecologia y obstetricia de mexico 1995;68:282-286. [4393714]
94. Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 2013;54(1):165-171. [4393716]
95. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland epilepsy and pregnancy registers. J Neurol Neurosurg Psychiatry 2014;0:1-6. [4393717]
96. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006;67:1876-1879. [4393718]
97. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy. Neurology 2008;71:272-276. [4393719]
98. Mawhinney E, Campbell J, Craig J, et al. Valproate and the risk for congenital malformations: Is formulation and dosage regime important?. Seizure 2012;21:215-218. [4393720]
99. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: Results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80:400-405. [4393721]
100. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198. [4393722]
101. Waters CH, Belai Y, Gott PS, Shen P, DeGiorgio CM. Outcomes of Pregnancy Associated With Antiepileptic Drugs. Arch Neurol 1994;51:250-253. [4393724]
102. Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine & Child Neurology 2000;42:87-92. [4393726]
103. Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptics and the development of congenital anomalies. Neurology 1992;42(5):132-140. [4393728]
104. Annegers J, Elveback L, Hauser W, Kurland L. Do anticonvulsants have a teratogenic effect?. Archives of Neurology 1974;31:364-373. [4393730]
105. Annegers J, Elveback L, Hauser W, Kurland L. Epilepsy anticonvulsants and malformations. Birth defects original article series 1975;11(5):157-160. [4393731]
106. Artama M, Gissler M, Malm H, Ritvanen A, The Drug and Pregnancy Group. Effects of Maternal Epilepsy and Antiepileptic Drug Useduring Pregnancy on Perinatal Health in Offspring:Nationwide, Retrospective Cohort Study in Finland. Drug Safety 2013;36:359-369. [4393733]
107. Arteaga-Vazquez J, Luna-Munoz L, Mutchinick OM. Congenital malformations in the offspring of epileptic mothers with and without anticonvulsant treatment [Malformaciones congenitas en hijos de madres epilepticas con y sin tratmiento con anticonvulsivantes]. Salud Publica Mexico 2012;54:579-86. [4393735]
108. Baermig H. Epilepsy and pregnancy. Geburtshilfe und Frauenheilkunde 1973;33:203-204. [4393737]
109. Canun-Serrano S, Zafra-De La Rosa G, Landeros-Velazquez G, Givaudan-Moreno M. Anticonvulsants in pregnancy [Anticonvulsivos y embarazo]. Bol Med Hol Infant Mex 1986;43(4):219-227. [4393739]
110. Castilla-Puentes R, Ford L, Manera L, Kwarta R, Ascher S, Li Q. Topiramate monotherapy use in women with and without epilepsy: Pregnancy and neonatal outcomes. Epilepsy Research 2014;108:717-724. [4393741]
111. Dobos M, Schuler D, Marosfi S, Bogathy B. Congenital malformations reported in children born to women with epilepsy [Veleszuletett fejlodesi rendellenessegek visagalata epilepszias anyak utodaiban]. Orvosi Hetilap 1985;126(37):2267-72. [4393743]
112. Elshove J, van Eck, J. Congenital abnormalities, cleft lip and cleft palate in particular, in children of epileptic mothers [Aangeboren misvormingen, met name gespleten lip met of zonder gespleten verhemelte, bij kinderen van moeders met epilepsie]. Nederlands Tijdschrift voor Geneeskunde 1971;115(33):1371-5. [4393745]
113. Holmes L, Harvey E, Brown K, Hayes A, Khoshbin S. Anticonvulsant teratogenesis: 1. A study design for newborn infants. Teratology 1994;49:202-207. [4393747]
114. Jacobsen P, Henriksen T, Haubek D, Ostergaard J. Developmental Enamel Defects in Children Prenatally Exposed to Anti-Epileptic Drugs. PLos One 2013;8(3):e58213. [4393749]
115. Jacobsen P, Henriksen T, Haubek D, Ostergaard J. Prenatal Exposure to Antiepileptic Drugs and Dental Agenesis. PLos ONE 2014;9(1):e84420. [4393750]
116. Knight A, Rhind E. Epilepsy and pregnancy: A study of 153 pregnancies in 59 patients. Epilepsia 1975;16:99-110. [4393752]
117. Cunnington M. The International Lamotrigine Pregnancy Registry Update for the Epilepsy Foundation. Epilepsia 2004;45(11):1468. [4393755]
118. Cunnington M, Ferber S, Quartey G, International LamotriginePregnancy Registry Scientific Advisory Committee. Effect of Dose on the Frequency of Major Birth Defects Following Fetal Exposure to Lamotrigine Monotherapy in an International Observational Study. Epilepsia 2007;48(6):1207-1210. [4393754]
119. Lamotrigine Pregnancy Registry. Final report. http://pregnancyregistry.gsk.com/documents/lam_spring_2010_final_report.pdf 2010. [4393756]
120. Tennis P, Eldridge R, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary Results on Pregnancy Outcomes in Women Using Lamotrigine. Epilepsia 2002;43(10):1161-1167. [4393757]
121. Miskov S, Gjergja-Juraski R, Cvitanovic-Sojat L, et al. Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy - Aspects of pre-pregnancy counseling and drug monitoring. Acta Clinica Croatica 2009;48(3):271-281. [4393759]
122. Monson R, Rosenberg L, Hartz S, et al. Diphenylhydantoin and selected congenital malformations. The New England Journal of Medicine 1973;289(20):1049-1052. [4393761]
123. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin pregnancy registry. Epilepsy and Behavior 2003;4:310-317. [4393763]
124. Mostacci B, Piccinni C, Bisulli F, et al. Prevalence of antiepileptic drugs exposure in pregnant women in the emilia romagna region (Italy): Results from the espea (emilia romagna study on pregnancy and exposure to antiepileptic drugs). Epilepsia. 2014; Vol. 555:131-132. [4393765]
125. Murasaki O, Yoshitake K, Tachiki H, Nakane Y, Kaneko S. Reexamination of the teratological effect of antiepileptic drugs. The Japanese Journal of Psychiatry and Neurology 1988;42(3):592-593. [4393767]
126. Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, Sato T, Fukushima Y, Kumashiro H, Ono T, Takahasi T, Aoki Y, Kazamatsuri H, Masaaki I, Komai S, Seino M, Miyakoshi, Tanimura T, Hazama H, Kawahara R, Otsuki S, Hosokawa K, Inanaga, Nakazawa, Yamamoto K. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-680. [4393768]
127. Nakane Y. Congenital malformation among infants of epileptic mothers treated during pregnancy: the report of a collaborative study group in Japan. Folia Psychiatrica et Neurologica Japonica 1979;33(3):363-369. [4393769]
128. Pearse SB, Garcia Rodriguez LA, Hartwell C, Russell G. A Pregnancy Register of Patients Receiving Carbamazepine in the UK. Pharmacoepidemiology and Drug Safety 1992;1:321-325. [4393771]
129. Robert E, Robert J, Lapras C. Is valproic acid teratogenic? [L'acide valproique est-il teratogene?]. Revue Neurologique 1983;139(6-7):445-447. [4393773]
130. Starveld-Zimmerman A, van der Kolk W, Elshove J, Meinardi H. Teratogenicity of antiepileptic drugs. Clinical Neurology and Neurosurgery 1975;77(2):81-95. [4393775]
131. Veiby G, Daltveit A, Engelsen B, Gilhus N. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of Neurology 2014;261:579-588. [4393777]
132. Babic N, Jovic N. Postnatal concerns in children born to women with juvenile myoclonic epilepsy. Epilepsia. 2014; Vol. 55:128. [4393779]
133. Idriz Oglu Gulcebi M, Kucukibrahimoglu E, Demirkapi M, Gulhan R, Karaalp A, Goren Z, Onat F. Evaluation of antiepileptic drug use in the pregnant patients with epilepsy in a university hospital in Istanbul. Epilepsia. 2014; Vol. 55:116-117. [4393781]
134. Jones KL, Johnson KA, Chambers CC. Pregnancy outcome in women treated with phenobarbital monotherapy. Teratology 1992;45:452-453. [4393783]
135. Kaabi W, El Aidli S, Kastalli S, Lakhoua G, Zaiem A, Srairi S, Daghfous R. Pregnancy outcomes in women using antiepileptic drugs. Drug Safety. 2013; Vol. 36:9. [4393785]
136. Kutlu G, Erdal A, Aydogan S, Gomceli Y, Inan L. Follow up and treatment of women with epilepsy during pregnancy. Epilepsia. 2013; Vol. 54:127-128. [4393787]
137. Lazzaroni-Fossati F, De Toni T, Magnani M, Repetto E, Calvi A, Di Siena G. Intrauterine exposure to drugs. Analysis of a sample of newborn infants pretreated with anticonvulsants [ESPOSIZIONE IN UTERO A FARMACI]. Minerva pediatrica 1986;38(3-4):75-81. [4393789]
138. Midi I, Bulut B, Ozbek D, Ozden H, Agan K. Antiepileptic drug usage and the effects of them on the foetus in epileptic pregnant woman. Epilepsia. 2014; Vol. 55:132. [4393791]
139. Midi I, Cetinkaya D, Ozden H, Agan K. Pregnant women with epilepsy: 43 patients results in 1 year period. Epilepsia. 2013; Vol. 54:131. [4393792]
140. Shvartzman P, Oren B, Keinan A, Adar H. Congenital malformations and anticonvulsant therapy in pregnancy. Harefuah 1986;110(8):377-80. [4393794]
141. Vlasov P, Petrukhin V, Karlov V, Krasnopolski V, Melnikov A, Tsivtsivadze E. Antiepileptic drug therapy during pregnancy and obstetric outcomes in Moscow region: Comparing of 1998 and 2013 years. Epilepsia. 2014; Vol. 55:130. [4393796]
142. Ackers R, Besag FMC, Wade A, Murray ML, Wong ICK. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Archives of Disease in Childhood 2009;94:443-447.
143. Adab N, Tudur Smith C, Vinten J, Williamson PR, Winterbottom JB. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004848]
144. Alsaada AMS, Chaudhry SA, Koren G. First trimester exposure to topiramate and the risk of oral clefts in the offspring: A systematic review and meta-analysis.. Reproductive Toxicology 2015;53:45-50.
145. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DB, Pellock JM, Harrod MJ, Lammer EJ, Majewska F, Schinzel A, Tonello HV, Hanson JW. Verification of the fetal valproate syndrome phenotype. American Journal of Medical Genetics 1988;29:171-185.
146. Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005;64:1874-1878.
147. Bossi L. Neonatal period including drug disposition in new borns: review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D editor(s). Epilepsy, Pregnancy and the Child. New York: Ravens Press, 1982:327-42.
148. Brent RL. Environmental Causes of Human Congenital Malformations: The Pediatrician's Role in Dealing With These Complex Clinical Problems Caused by a Multiplicity of Environmental and Genetic Factors. Pediatrics 2004;113(4):957-968.
149. Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, Tudur Smith C, Marson AG. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2]
150. Charlton RA, Cunnington MC, de Vries CS, Weil JG. Data resources for investigating drug exposure during pregnancy and associated outcomes: the general practice research database (GPRD) as an alternative to pregnancy registries. Drug Safety 2008;31(1):39-51.
151. Charlton RA, Neville AJ, Jordan S, Pierini P, Damase-Michel C, Klungsøyr K, Nybo Andersen A-M, Vinkel Hansen A, Gini R, Bos JHJ, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-van den Berg LTW, de Vries CS. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiology and drug safety 2014;23(6):586-94.
152. Chaudhry SA, Jong Gt, Koren G. The fetal safety of Levetiracetam: a systematic review. Reproductive Toxicology 2014;46:40-45.
153. Dean JCS, Moore SJ, Turnpenny PD. Developing diagnostic criteria for the fetal anticonvulsant syndromes. Seizure 2000;9:233-234.
154. DiLiberti JH. Fetal valproate syndrome: consistent facial changes in infants exposed to sodium valproate. Clinical Research 1983;31(1):127A.
155. The EURAP STUDY GROUP. Seizure control and treatment in pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry. Neurology 2006;66:354-360.
156. EUROCAT Working Group. EUROCAT Surveillance of Congenital Anomalies. EUROCAT guide 1.3 and reference documents instructions for the registration and surveillance of congenital anomalies. http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf Accessed August 2015.
157. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
158. Hauser W, Hesdorffer D. Epilepsy: Frequency, causes and consequences. New York: Demos Publications, 1990.
159. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
160. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine 2010;362:2185-93.
161. Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, de Jong-van den Berg L, for the EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. British Medical Journal 2010;341:c6581.
162. Ku CS, Naidoo N, Wu M, Soong R. Studying the epigenome using next generation sequencing. Journal of Medical Genetics 2011;48(11):721-730.
163. Man S-L, Petersen I, Thompson M, Nazareth I. Antiepileptic Drugs during Pregnancy in Primary Care: A UK Population Based Study. PLoS One 2012;7:e52339.
164. Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, Hernandez-Diaz S and National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral clefts. American Journal of Obstetrics and Gynecology 2012;207(5):405.e1-405.e7.
165. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81:1-13.
166. Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A, Liporace JD, Sam M, Kalayjian LA, Thurman DJ, Moore E, Loring DW, for the NEAD Study Group. Antiepileptic drug use in women of childbearing age. Epilepsy and Behaviour 2009;15:339-43.
167. D Mines, Tennis P, Curkendall SM, Li D, Peterson C, Andrews EB, Calingaert B, Chen H, Deshpande G, Esposito DB, Everage N, Holick CN, Meyer NM, Nkhoma ET, Quinn S, Rothman KJ, Chan KA. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiology and drug safety 2014;23:1017-1025.
168. Mølgaard-Nielsen D, Hviid A. Newer-Generation Antiepileptic Drugsand the Risk of Major Birth Defects. JAMA 2011;305(19):1996-2002.
169. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10(7):609-17.
170. Wen X, Meador K, Hartzema A. Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. Antiepileptic drug use by pregnant women enrolled in Florida Medicaid 2015;84:1-7.
171. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica 2004;93:174-176.
172. Yerby MS. Pregnancy, teratogenesis and epilepsy. Neurological Clinics 1994;12(4):749-71.
173. Pulman J, Bromley R, Adab N, Greenhalgh J, McKay AJ, Tudur Smith C, Dickson RC, Marson AG. Treatment for epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD010224]